CHEERS checklist—Items to include when reporting economic evaluations of health interventions

	Item		Reported on page No/
Section/item	No	Recommendation	line No
Title and abstract			
Title	1	Identify the study as an economic evaluation or use more specific terms such as "cost-effectiveness analysis", and describe the interventions compared.	page 1, line 2 and 3
Abstract	2	Provide a structured summary of objectives, perspective, setting, methods (including study design and inputs), results (including base case and uncertainty analyses), and conclusions.	page 2
Introduction			
Background and objectives	3	Provide an explicit statement of the broader context for the study. Present the study question and its relevance for	page 3, line 74-86 Page 3, line 81-86
		health policy or practice decisions.	
Methods			
Target population and subgroups	4	Describe characteristics of the base case population and subgroups analysed, including why they were chosen.	page 4, line 107-112
Setting and location	5	State relevant aspects of the system(s) in which the decision(s) need(s) to be made.	page 4, line 104-105
Study perspective	6	Describe the perspective of the study and relate this to the costs being evaluated.	page 5, line 132-133
Comparators	7	Describe the interventions or strategies being compared and state why they were chosen.	page 5, line 135-140
Time horizon	8	State the time horizon(s) over which costs and consequences are being evaluated and say why appropriate.	page 6, line 154-162
Discount rate	9	Report the choice of discount rate(s) used for costs and outcomes and say why appropriate.	not applicable
Choice of health outcomes	10	Describe what outcomes were used as the measure(s) of benefit in the evaluation and their relevance for the type of analysis performed.	Page 6, line 155-163
Measurement of effectiveness	11a	Single study-based estimates: Describe fully the design features of the single effectiveness study and why the single study was a sufficient source of clinical effectiveness data.	not applicable
	11b	Synthesis-based estimates: Describe fully the methods used for identification of included studies and synthesis of clinical effectiveness data.	not applicable
Measurement and valuation of preference based outcomes	12	If applicable, describe the population and methods used to elicit preferences for outcomes.	not applicable
Estimating resources and costs	13a	Single study-based economic evaluation: Describe approaches used to estimate resource use associated with the alternative interventions. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.	
	13b	Model-based economic evaluation: Describe approaches and data sources used to estimate	

	Item		Reported on page No/
Section/item	No	Recommendation	line No
		resource use associated with model health states.	
		Describe primary or secondary research methods for	
		valuing each resource item in terms of its unit cost.	
		Describe any adjustments made to approximate to	
		opportunity costs.	
Currency, price date, and conversion	14	Report the dates of the estimated resource quantities	page 162-163
		and unit costs. Describe methods for adjusting	
		estimated unit costs to the year of reported costs if	
		necessary. Describe methods for converting costs into	
Chaire of 1.1	15	a common currency base and the exchange rate.	
Choice of model	15	Describe and give reasons for the specific type of	not applicable
		decision-analytical model used. Providing a figure to	
A	16	show model structure is strongly recommended. Describe all structural or other assumptions	nat annliaghla
Assumptions	16	·	not applicable
A 1 12 1 12 1	17	underpinning the decision-analytical model.	not annlicable
Analytical methods	17	Describe all analytical methods supporting the	not applicable
		evaluation. This could include methods for dealing with skewed, missing, or censored data; extrapolation	
		methods; methods for pooling data; approaches to	
		validate or make adjustments (such as half cycle	
		corrections) to a model; and methods for handling	
		population heterogeneity and uncertainty.	
Results		population neterogeneity and uncertainty.	
	18	Report the values, ranges, references, and, if used,	nago 6 lino 155 161
Study parameters	10	probability distributions for all parameters. Report	page 6, line 155-161
		reasons or sources for distributions used to represent	
		uncertainty where appropriate. Providing a table to	
		show the input values is strongly recommended.	
Incremental costs and	19	For each intervention, report mean values for the	Mean costs in
outcomes	19	main categories of estimated costs and outcomes of	Table 5 (page 13-14)
outcomes		interest, as well as mean differences between the	Table 5 (page 15-14)
		comparator groups. If applicable, report incremental	
		cost-effectiveness ratios.	
Characterising uncertainty	20a	Single study-based economic evaluation: Describe the	not applicable
Characterising uncertainty	200	effects of sampling uncertainty for the estimated	not applicable
		incremental cost and incremental effectiveness	
		parameters, together with the impact of	
		methodological assumptions (such as discount rate,	
		study perspective).	
	20b	Model-based economic evaluation: Describe the	not applicable
	200	effects on the results of uncertainty for all input	not applicable
		parameters, and uncertainty related to the structure	
		of the model and assumptions.	
Characterising	21	If applicable, report differences in costs, outcomes, or	not applicable
heterogeneity	21	cost-effectiveness that can be explained by variations	not applicable
neterogeneity		between subgroups of patients with different baseline	
		characteristics or other observed variability in effects	
		that are not reducible by more information.	
Discussion			
Study findings, limitations,	22	Summarise key study findings and describe how they	Page 15-16, line 1-68
generalisability, and		support the conclusions reached. Discuss limitations	. 565 25 20, 1116 2 00
current knowledge		and the generalisability of the findings and how the	
and the day		findings fit with current knowledge.	
Other		0	
Source of funding	23	Describe how the study was funded and the role of	Page 1, lines 16-20
		The state of the s	. 000 -,03 10 20

	Item		Reported on page No/
Section/item	No	Recommendation	line No
		the funder in the identification, design, conduct, and reporting of the analysis. Describe other non-monetary sources of support.	
Conflicts of interest	24	Describe any potential for conflict of interest of study contributors in accordance with journal policy. In the absence of a journal policy, we recommend authors comply with International Committee of Medical Journal Editors recommendations.	Information provided via the submission system and on Page 1, lines 22-23

For consistency, the CHEERS statement checklist format is based on the format of the CONSORT statement checklist